SARS-CoV-2 T-cell vaccine VB10.2210 induces broad T-cell responses in a phase 1/2 open-label clinical trial. - Tøndel C; Jenum S; Tonby K; Christensen EE; Cox RJ; Onyango TB; Skeie LG; Robins H; Klinger M; Banbury B; Bello T; Osborne EJ; et al. (Vaccine, 2026)